| 1 |
34344199 | Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC. | 2022 Apr |
1 |
| 2 |
35066105 | Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients. | 2022 Apr |
1 |
| 3 |
35462930 | Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports. | 2022 |
1 |
| 4 |
33641722 | Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib. | 2021 Mar |
1 |
| 5 |
34203709 | Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer. | 2021 Jun 15 |
2 |
| 6 |
34994624 | Divergent RET- and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC: A Case Report. | 2021 Nov |
1 |
| 7 |
31911548 | Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. | 2020 Jun 1 |
1 |
| 8 |
33173309 | A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report. | 2020 |
2 |